Livzon Pharmaceutical Group Inc
SZSE:000513
Livzon Pharmaceutical Group Inc
SZSE:000513
Price:
40.1 CNY
1.75%
Market Closed
Updated:
May 3, 2024
Livzon Pharmaceutical Group Inc
Operating Income
|
Livzon Pharmaceutical Group Inc
Operating Income Peer Comparison
Comparables:
H
3692
600436
600276
000538
C
300765
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Livzon Pharmaceutical Group Inc
SZSE:000513
|
Operating Income
¥2.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
13%
|
CAGR 10-Years
14%
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Income
¥3.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Operating Income
¥3.3B
|
CAGR 3-Years
22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
21%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Income
¥3.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
10%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Income
¥3.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
6%
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Operating Income
¥787.7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
See Also
What is Livzon Pharmaceutical Group Inc's Operating Income?
Operating Income
2.1B
CNY
2.1B
CNY
Based on the financial report for Dec 31, 2023, Livzon Pharmaceutical Group Inc's Operating Income amounts to 2.1B CNY.
What is Livzon Pharmaceutical Group Inc's Operating Income growth rate?
Operating Income CAGR 10Y
14%
14%
Over the last year, the Operating Income growth was 0%. The average annual Operating Income growth rates for Livzon Pharmaceutical Group Inc have been -2% over the past three years , 13% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
